Testing a new drug for safety in healthy volunteers
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial is testing a new drug called HXN5003 in healthy volunteers to find the safest dose and see how the body handles it. It's an early-stage study, so the main goal is safety, not treating a disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old
- Have a body mass index (BMI) between 18 and 32
- Be generally healthy — no major illnesses like diabetes, cancer, or heart disease
- Not be pregnant or breastfeeding
- Avoid taking any prescription or over-the-counter medications or supplements for a period before dosing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BYN-001 in two groups: healthy people and people with moderate to severe eczema (atopic dermatitis). The goal is to see if the drug is safe and how well it works.
This study tests a new investigational drug, called HRS-8797, in healthy people to see how safe it is and how the body processes it. It's an early-phase trial, so you may not directly benefit, but your participation can help find new treatments for future patients.
This early-stage trial tests a new experimental medicine called REGN20423 in two groups: healthy volunteers and people with atopic dermatitis (a chronic skin condition causing itching and inflammation). The trial aims to assess whether the medicine is safe and well-tolerated.
This trial tests an experimental medicine called QX-4533. The study has two parts: one tests the drug in healthy volunteers, and the other tests it in people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't responded well to standard creams. The goal is to see if the drug is safe and how well it works.
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
This study tests a new injected medication called XKH001 for people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't improved with standard creams. The goal is to see if it can reduce the severity of eczema and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.